Daiichi Sankyo Sarah Cannon Announce Initial Results From Phase 1 Study Of Ds-6000 To Treat Advanced Ovarian Cancer Or Renal Cell Carcinoma

Daiichi Sankyo And Sarah Cannon Research Institute (Sarah Cannon) Announced That Initial Results From The First-In-Human Phase 1 Study Of Ds-6000, A Cdh6 Directed Dxd Antibody Drug Conjugate (Adc), Suggest Early Clinical Activity In Patients With Advanced Ovarian Cancer Or Renal Cell Carcinoma With Disease Progression Following Standard Of Care Treatment. The Data Were Presented Today In An Oral Session (Abstract #3002) At The American Society Of Clinical Oncology (#Asco22) Annual Meeting.Patients With Advanced Ovarian Cancer Or Renal Cell Carcinoma May Have Disease Progression After Initial Treatments And There Is A Need For New Therapeutic Approaches For Recurrent Disease, As Five-Year Survival Rates In The Us Are Low At 30% And 15%, Respectively. The Cdh6 Protein Is Significantly Overexpressed In Ovarian Cancer And Renal Cell Carcinoma And Has Been Identified As A Promising Therapeutic Target.Preliminary Safety And Efficacy Results Of Ds-6000 Were Reported From The Dose Escalation Part Of The Phase 1 Trial In 30 Heavily Pretreated Patients, Including 21 Patients With Advanced Ovarian Cancer, One Of Which Was Missing A Primary Diagnosis Of Ovarian Cancer, And Nine Patients With Renal Cell Carcinoma.The Safety And Tolerability Of Ds-6000 Was Evaluated At Increasing Dose Levels From 1.6 Mg/Kg To 9.6 Mg/Kg With Two Dose-Limiting Toxicities Observed At The 9.6 Mg/Kg Dose (Grade 3 Febrile Neutropenia And Grade 4 Thrombocytopenia). The Most Common Treatment-Related Emergent Adverse Events (Teaes) (= 10% Of Patients) Reported Were Nausea (60.0%), Fatigue (56.7%), Vomiting (30.0%), Neutrophil Count Decrease (23.3%), Decreased Appetite (20.0%), And Diarrhea (13.3%). Grade = 3 Teaes Occurred In Seven Patients (23.3%), The Most Common Of Which Were Neutrophil Count Decrease (16.7%), Anemia (6.7%) And Febrile Neutropenia (6.7%). One Patient Experienced Grade 2 Pneumonitis At The 9.6 Mg/Kg Dose That Led To Treatment Discontinuation.Preliminary Efficacy Resultsin 20 Evaluable Patientsincluded Six Partial Responses (Prs) In Patients With Ovarian Cancer (N=5) And Renal Cell Carcinoma (N=1). Four Prs Were Confirmed And Two Are Awaiting Confirmation. Stable Disease Was Reported In 12 Patients With Platinum-Resistant Ovarian Cancer. Eight Ca125 Responses Were Observed In 17 Evaluable Patients With Ovarian Cancer, Based On The Gynecologic Cancer Intergroup (Gcig) Criteria

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!